Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 107-112

  Shiga, Yuhei ^a   Miura, Shin Ichiro ^a   Mitsutake, Ryoko ^a   Uehara, Yoshinari ^a   Inoue, Asao ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Inoue Hospital   (Japan)

Author keywords

Angiotensin II receptor blocker; blood pressure; brain natriuretic peptide; diuretic; losartan hydrochlorothiazide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CHLORINE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; SODIUM; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; PULSE RATE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

AGED; BLOOD PRESSURE; BODY WEIGHT; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; NATRIURETIC PEPTIDE, BRAIN; SYSTOLE;

EID: 84856901815     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311415135     Document Type: Article

References (18)

1. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. (ASCOT Investigators). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
2. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. (Japanese Society of Hypertension Committee). The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
3. Martina B, Dieterle T, Weinbacher M and Battegay E. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92: 110-114. (Pubitemid 30135940)
4. Vogt L, Waanders F, Boomsma F, de Zeeuw D and Navis G.Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007.
5. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM and Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration comparedwith individual components. Arch Intern Med 1996; 156: 278-285. (Pubitemid 26058478)
6. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI and Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
7. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. (ESC Committee for Practice Guidelines (CPG)). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-989.
8. Soualmia H, Ayadi I, Omar S, Feki M, Drissa H, Mebazaa A, et al. Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension. Clin Lab 2009; 55: 120-127.
9. Burnier M. Angiotensin II type 1 receptor blockers (review). Circulation 2001; 103: 904-912. (Pubitemid 32163892)
10. Miura S, Karnik SS and Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.J Renin Angiotensin Aldosterone Syst 2011; 12: 1-7.
11. Fabia MJ, Abdilla N, Oltra R, Fernandez C and Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327-1336. (Pubitemid 46924066)
12. Kato J and Eto T. Diuretics in the LIFE study. Lancet 2004; 364: 413.
13. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002. (Pubitemid 38579904)
14. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L and Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 2: 457-464. (Pubitemid 39157547)
15. Suzuki M, Hamada M, Yamamoto K, Kazatani Y andHiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25: 669-676. (Pubitemid 35153753)
16. Levin ER, Gardner DG and Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328. (Pubitemid 28366422)
17. Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims HM, Kjeldsen SE, et al. Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. J Clin Hypertens 2006; 8: 169-173.
18. van Brummelen P, Man in 't Veld AJ and Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980; 27: 328-336.